Literature DB >> 26830290

Effect of the Anti-depressant Sertraline, the Novel Anti-seizure Drug Vinpocetine and Several Conventional Antiepileptic Drugs on the Epileptiform EEG Activity Induced by 4-Aminopyridine.

Maria Sitges1, Blanca Irene Aldana2, Ronald Charles Reed3.   

Abstract

Seizures are accompanied by an exacerbated activation of cerebral ion channels. 4-aminopyridine (4-AP) is a pro-convulsive agent which mechanism of action involves activation of Na(+) and Ca(2+) channels, and several antiepileptic drugs control seizures by reducing these channels permeability. The antidepressant, sertraline, and the anti-seizure drug vinpocetine are effective inhibitors of cerebral presynaptic Na(+) channels. Here the effectiveness of these compounds to prevent the epileptiform EEG activity induced by 4-AP was compared with the effectiveness of seven conventional antiepileptic drugs. For this purpose, EEG recordings before and at three intervals within the next 30 min following 4-AP (2.5 mg/kg, i.p.) were taken in anesthetized animals; and the EEG-highest peak amplitude values (HPAV) calculated. In control animals, the marked increase in the EEG-HPAV observed near 20 min following 4-AP reached its maximum at 30 min. Results show that this epileptiform EEG activity induced by 4-AP is prevented by sertraline and vinpocetine at a dose of 2.5 mg/kg, and by carbamazepine, phenytoin, lamotrigine and oxcarbazepine at a higher dose (25 mg/kg). In contrast, topiramate (25 mg/kg), valproate (100 mg/kg) and levetiracetam (100 mg/kg) failed to prevent the epileptiform EEG activity induced by 4-AP. It is concluded that 4-AP is a useful tool to elicit the mechanism of action of anti-seizure drugs at clinical meaningful doses. The particular efficacy of sertraline and vinpocetine to prevent seizures induced by 4-AP is explained by their high effectiveness to reduce brain presynaptic Na(+) and Ca(2+) channels permeability.

Entities:  

Keywords:  Carbamazepine; Lamotrigine; Levetiracetam; Oxcarbazepine; Phenytoin; Topiramate; Valproic acid

Mesh:

Substances:

Year:  2016        PMID: 26830290     DOI: 10.1007/s11064-016-1840-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  41 in total

1.  Selective suppression of the slow-inactivating potassium currents by nootropics in molluscan neurons.

Authors:  Julia V Bukanova; Elena I Solntseva; Vladimir G Skrebitsky
Journal:  Int J Neuropsychopharmacol       Date:  2002-09       Impact factor: 5.176

2.  Epilepsy: Bidirectional link between epilepsy and psychiatric disorders.

Authors:  Marco Mula
Journal:  Nat Rev Neurol       Date:  2012-04-17       Impact factor: 42.937

3.  The anti-seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL-1β and TNF-α expression in rat hippocampus.

Authors:  Carlos D Gómez; Rudolf M Buijs; María Sitges
Journal:  J Neurochem       Date:  2014-06-27       Impact factor: 5.372

Review 4.  Drug treatment of epilepsy in adults.

Authors:  Dieter Schmidt; Steven C Schachter
Journal:  BMJ       Date:  2014-02-28

5.  Comorbidity between temporal lobe epilepsy and depression: a [18F]MPPF PET study.

Authors:  A Lothe; A Didelot; A Hammers; N Costes; M Saoud; F Gilliam; P Ryvlin
Journal:  Brain       Date:  2008-09-02       Impact factor: 13.501

6.  Kainic acid and 4-aminopyridine seizure models in mice: evaluation of efficacy of anti-epileptic agents and calcium antagonists.

Authors:  C L Cramer; M L Stagnitto; M A Knowles; G C Palmer
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

7.  Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region.

Authors:  Eduardo D Martín; Miguel A Pozo
Journal:  Epilepsia       Date:  2003-11       Impact factor: 5.864

8.  Effects of pentylenetetrazole and 4-aminopyridine on the auditory brainstem response (ABR) and on the hearing sensitivity in the guinea pig in vivo.

Authors:  Vladimir Nekrassov; María Sitges
Journal:  Epilepsy Res       Date:  2003-03       Impact factor: 3.045

9.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

10.  Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing.

Authors:  Maria Sitges; V Nekrassov
Journal:  Clin Neurophysiol       Date:  2004-12       Impact factor: 3.708

View more
  6 in total

1.  Systemic exposure to Ginkgo biloba extract in male F344/NCrl rats: Relevance to humans.

Authors:  Suramya Waidyanatha; Esra Mutlu; Seth Gibbs; Billie Stiffler; Jon Andre; Brian Burback; Cynthia V Rider
Journal:  Food Chem Toxicol       Date:  2019-06-14       Impact factor: 6.023

2.  Embryo-fetal development studies with the dietary supplement vinpocetine in the rat and rabbit.

Authors:  Natasha Catlin; Suramya Waidyanatha; Eve Mylchreest; Lutfiya Miller-Pinsler; Helen Cunny; Paul Foster; Vicki Sutherland; Barry McIntyre
Journal:  Birth Defects Res       Date:  2018-02-19       Impact factor: 2.344

3.  Systemic exposure of vinpocetine in pregnant Sprague Dawley rats following repeated oral exposure: An investigation of fetal transfer.

Authors:  Suramya Waidyanatha; Heather Toy; Natalie South; Seth Gibbs; Esra Mutlu; Brian Burback; Barry S McIntyre; Natasha Catlin
Journal:  Toxicol Appl Pharmacol       Date:  2017-11-15       Impact factor: 4.219

4.  KB-R7943 reduces 4-aminopyridine-induced epileptiform activity in adult rats after neuronal damage induced by neonatal monosodium glutamate treatment.

Authors:  Mariana Hernandez-Ojeda; Monica E Ureña-Guerrero; Paola E Gutierrez-Barajas; Jazmin A Cardenas-Castillo; Antoni Camins; Carlos Beas-Zarate
Journal:  J Biomed Sci       Date:  2017-05-09       Impact factor: 8.410

5.  Toxicological evaluation of convulsant and anticonvulsant drugs in human induced pluripotent stem cell-derived cortical neuronal networks using an MEA system.

Authors:  A Odawara; N Matsuda; Y Ishibashi; R Yokoi; I Suzuki
Journal:  Sci Rep       Date:  2018-07-10       Impact factor: 4.379

6.  Personalized medicine: Vinpocetine to reverse effects of GABRB3 mutation.

Authors:  Santoshi Billakota; J Michael Andresen; Bryant C Gay; Gregory R Stewart; Nikolai B Fedorov; Aaron C Gerlach; Orrin Devinsky
Journal:  Epilepsia       Date:  2019-11-22       Impact factor: 5.864

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.